tailieunhanh - Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: Realworld analysis of Korean national database

A randomized clinical trial has found that the addition of erlotinib to gemcitabine (GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national population-based retrospective study was to compare the effectiveness of GEM-E to GEM alone for pancreatic cancer patients in real clinical practice. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN